Immunovant (IMVT) Proxy filing summary

Executive summary

• Annual meeting scheduled for September 2, 2026, with virtual participation available.

• Shareholders are invited to vote on key proposals, including director elections, auditor ratification, and executive compensation.

Voting matters and shareholder proposals

• Election of three directors to serve until the 2027 annual meeting: Jacob Bauer, Douglas Hughes, and Robert Susman.

• Ratification of Ernst & Young LLP as independent auditor for the fiscal year ending March 31, 2027.

• Advisory vote on executive compensation for named executive officers.

• Proxy holders may vote on other business arising at the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all three director nominees.

• Directors to serve one-year terms, subject to re-election at the next annual meeting.